Comparative Pharmacology
Head-to-head clinical analysis: SOYACAL 10 versus SOYACAL 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOYACAL 10 versus SOYACAL 20.
SOYACAL 10% vs SOYACAL 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Soybean oil provides essential fatty acids (linoleic and linolenic acids) as a caloric source and prevents essential fatty acid deficiency; intravenous fat emulsions are metabolized to free fatty acids, which are oxidized for energy or stored as triglycerides.
Soybean oil emulsion provides essential fatty acids (linoleic and linolenic acid) as a caloric source and substrate for lipid synthesis and membrane integrity.
Intravenous infusion: 500 mL/day as part of parenteral nutrition, adjusted to meet individual caloric and protein needs. Typical rate: 0.5-1.5 mL/kg/h.
Intravenous infusion: 20% lipid emulsion, initial dose 1 g/kg/day (5 mL/kg/day) infused over 12-24 hours; maximum 2.5 g/kg/day (12.5 mL/kg/day).
None Documented
None Documented
3.5 hours (terminal elimination half-life in adults; may be prolonged in preterm infants or hepatic dysfunction).
The terminal elimination half-life of the triglyceride component is approximately 1 to 2 hours under steady-state conditions. Clinical context: In critically ill patients, clearance may be reduced, prolonging half-life.
Soyacal 10% (soybean oil emulsion) is metabolized via β-oxidation and cleared from the bloodstream by lipoprotein lipase; <5% excreted renally, ~95% eliminated as CO2 via lungs, minimal fecal excretion.
Soybean oil in SOYACAL 20% is metabolized and eliminated primarily through oxidation and incorporation into body tissues. Less than 5% is excreted unchanged in urine. Biliary/fecal excretion of metabolites is minimal.
Category C
Category C
Intravenous fat emulsion
Intravenous fat emulsion